HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70341 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Mengxin Jiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Ovarian Neoplasms, Adenocarcinoma, Clear Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Science and Technology Agency.
Abstract (Originalsprache)
Ovarian clear cell carcinoma (CCC) is an aggressive subtype of ovarian cancer that is resistant to conventional chemotherapy, resulting in poor prognosis. CCC develops from endometriosis, which exposes tumor cells to a hypoxic microenvironment, thereby highlighting the critical role of hypoxia in ovarian CCC progression. Thus, identifying novel therapeutic targets, particularly those associated with hypoxia, is important. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian CCC remains unclear. This study assessed the prognostic and functional significance of HIF2A in ovarian CCC and investigated its potential as a therapeutic target. Inhibiting HIF2A significantly suppressed ovarian CCC tumor growth through a genetic knockdown cell line as well as pharmacological inhibition using a novel HIF2A inhibitor, NKT2152. In vitro experiments showed that HIF2A suppression enhanced mitochondrial respiration and increased mitochondrial reactive oxygen species production alongside the downregulation of HIF2A target genes. Moreover, treatment with NKT2152 significantly reduced tumor growth in both cell line‐derived and patient‐derived xenograft models. In conclusion, our findings provide novel insights into the prognostic and functional role of HIF2A in ovarian CCC and underscore its potential as a promising therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan.
- Department of Obstetrics and Gynecology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
- Biology Department, NiKang Therapeutics, Wilmington, Delaware, USA.
ORCID-Profile: Mengxin Jiang, Ken Yamaguchi, Koji Yamanoi
Förderung
- Japan Science and Technology Agency
Zitieren
APA
Jiang, M., Yamaguchi, K., Hamada, K., Hosoe, Y., Mise, Y., Kitamura, S., Liu, Z., Wei, H., Gao, Z., Taki, M., Yamanoi, K., Murakami, R., Mizuno, R., Miyamoto, T., Hamanishi, J., & Mandai, M. (2026). HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70341
Vancouver
Jiang M, Yamaguchi K, Hamada K, Hosoe Y, Mise Y, Kitamura S, et al. HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma. International Journal of Cancer. 2026. doi:10.1002/ijc.70341
BibTeX
@article{Jiang2026,
author = {Jiang, Mengxin and Yamaguchi, Ken and Hamada, Kohei and Hosoe, Yuko and Mise, Yuka and Kitamura, Sachiko and Liu, Zhihong and Wei, Hairong and Gao, Zhenhai and Taki, Mana and Yamanoi, Koji and Murakami, Ryusuke and Mizuno, Rin and Miyamoto, Taito and Hamanishi, Junzo and Mandai, Masaki},
title = {HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70341}
}
EUVIMED